The Preventing Animal Abuse and Waste (PAAW) Act adds a new section to the Public Health Service Act that bars the Director of the National Institutes of Health from conducting or supporting any research that causes "significant pain or distress" to a dog or cat. The bill defines that phrase by reference to the Department of Agriculture’s Pain and Distress Categories D and E (or successor categories under the Animal Welfare Act).
This change reaches both intramural NIH work and extramural grants and contracts because it prohibits the NIH Director from both conducting and supporting research. For institutions and investigators who currently rely on canine or feline models for studies that meet USDA pain categories D or E, the bill would force programmatic changes, re-scoping of protocols, or the search for non-NIH funding or alternative models; NIH itself will need to revise funding terms and review processes to enforce the prohibition.
At a Glance
What It Does
The bill inserts Section 447E into the Public Health Service Act and prohibits the NIH Director from conducting or supporting any research that causes "significant pain or distress" to a dog or cat. It ties that standard explicitly to USDA Pain and Distress Categories D and E (or successors under AWA section 13).
Who It Affects
The prohibition covers NIH intramural research and all NIH-funded extramural projects that involve dogs or cats; principal investigators, institutional animal care and use committees (IACUCs), veterinary research centers, and contract research organizations that perform canine or feline studies will be directly affected. Program officers, grant administrators, and compliance offices must operationalize the new rule.
Why It Matters
By adopting USDA pain categories as the legal trigger, the bill creates a bright-line constraint on federally supported studies that involve severe or unrelieved pain in dogs and cats. That shift could redirect NIH funding away from some animal models, increase demand for validated alternatives, and require rapid changes to grant conditions and protocol review practices.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The PAAW Act is short and specific: it adds a new statutory bar preventing the NIH Director from conducting or supporting any research that causes "significant pain or distress" to a dog or cat. The bill defines that phrase by reference to USDA Pain and Distress Categories D and E (or successor categories developed under the Animal Welfare Act), and it takes effect 90 days after enactment.
Operationally, the prohibition reaches both NIH’s intramural laboratories and the extramural grant and contract portfolio because the statute forbids the Director from either conducting or supporting covered research. NIH will therefore need to change award terms and review criteria to ensure that no funded project assigns a D or E pain category to a dog or cat; intramural programs will have to amend or terminate ongoing protocols that fall within those categories.
The statutory text contains no waiver, exemption, or grandfathering clause.The bill relies on an external regulatory classification—the USDA’s pain and distress categories—rather than creating a new NIH-specific standard. That linkage matters because USDA categories are embedded in the Animal Welfare Act framework and become the legal yardstick here; NIH will need to decide how to map IACUC determinations, grant application descriptions, and protocol classifications to those USDA categories for compliance and reporting.
The absence of an enforcement mechanism beyond the statutory prohibition leaves implementation details—award conditions, monitoring, and remedial steps—to NIH policy-making and administrative practice.Because the ban is limited to dogs and cats and to studies meeting the D/E threshold, projects that use other species or that are classified in lower pain categories will not be affected on their face. Still, researchers who rely on canine or feline models for certain translational studies will face programmatic choices: re-design studies to eliminate D/E-level procedures, substitute validated alternatives, seek non-NIH funding, or stop the line of research.
That practical reshaping of NIH-supported portfolios is the primary effect of the bill.
The Five Things You Need to Know
The bill amends the Public Health Service Act by adding Section 447E, which bars the NIH Director from conducting or supporting research that causes "significant pain or distress" to a dog or cat.
The statute defines "research that causes significant pain or distress" by reference to USDA Pain and Distress Categories D and E, or successor categories developed under section 13 of the Animal Welfare Act (7 U.S.C. 2143).
The prohibition covers both intramural NIH research and extramural support—language used is "conduct or support," giving the restriction the broadest programmatic reach within NIH authority.
The bill contains no waiver, exception, or grandfathering provision and becomes applicable 90 days after enactment, so ongoing NIH-funded projects that fall into D/E categories would be subject to the ban unless modified.
The text establishes the substantive ban but does not specify enforcement mechanisms, administrative remedies, or penalty provisions; implementation details (award conditions, monitoring, compliance steps) are left to NIH policy-making.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Establishes the Act's public name as the "Preventing Animal Abuse and Waste Act" or "PAAW Act." This is purely nominal but signals legislative intent and frames subsequent statutory interpretation in public materials and rulemaking.
Prohibition on research causing significant pain or distress to dogs and cats
Adds a statutory bar that the Director of NIH "may not conduct or support" any research that causes significant pain or distress to a dog or cat. The phrasing "conduct or support" matters: it reaches intramural activity under NIH control and extramural grants, contracts, and cooperative agreements that NIH funds. Because the restriction is cast at the level of the NIH Director’s authority, implementation will require agency-level policy changes—revised award terms, grant review criteria, intramural protocol approvals, and compliance checks—rather than leaving enforcement to individual investigators or institutions.
Definition tied to USDA pain categories; successor categories
Defines the triggering standard by pointing to the USDA Pain and Distress Categories D and E (or successor categories developed under AWA section 13). That cross-reference imports an external regulatory taxonomy into NIH funding law, which creates operational questions: which office determines category assignment for a given protocol, how NIH maps its IACUC decisions to USDA categories, and how NIH will verify category assignments during peer review and post-award monitoring. The provision also contemplates future revisions to USDA categories by referring to successor categories, so compliance will track changes in USDA classification over time.
Effective date and immediate footprint
The amendment applies 90 days after enactment. That short lead time means NIH, grantees, and intramural programs will need rapid operational guidance to avoid noncompliance. The text provides no transitional authority or grandfathering, so NIH faces practical choices about handling ongoing protocols that currently assign D/E categories: amend, pause, reclassify, or terminate. Those choices will have budgetary and scientific consequences for affected projects.
This bill is one of many.
Codify tracks hundreds of bills on Science across all five countries.
Explore Science in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Dogs and cats used in federally funded research: the statute removes NIH support for studies that federal regulators classify in the highest pain/distress categories, reducing the number of NIH-funded experiments that intentionally inflict severe or unrelieved pain on these species.
- Animal-welfare organizations and advocates: the law codifies a clear federal constraint that aligns NIH funding policy with welfare priorities, giving advocacy groups a straightforward legal benchmark to monitor NIH-funded activity.
- Developers of alternative methods (in vitro, organoids, computational models): the ban increases demand for validated non-animal approaches that can replace canine or feline models in areas affected by the prohibition, potentially accelerating investment and validation work.
Who Bears the Cost
- NIH and its program offices: the agency must create and implement new compliance procedures, change award terms, revise program solicitations, and provide guidance to intramural labs and extramural grantees—administrative costs that are not addressed in the bill.
- Extramural investigators and institutions that use dogs or cats in D/E-level procedures: they will need to redesign protocols, seek alternative models, absorb delays or losses of NIH funding, or pursue other funders; veterinary schools and niche research centers are particularly exposed.
- Contract research organizations and veterinary centers that perform high-pain-category canine or feline work under NIH sponsorship: their pipelines of NIH-supported work could shrink, forcing business adjustments or pursuit of non-NIH clients.
Key Issues
The Core Tension
The bill pits a clear animal-welfare objective—ending federal support for canine and feline studies that inflict significant pain—against the pragmatic need for certain animal models in translational science. Tight statutory limits protect animals but can close research paths that currently yield human-health insights; the harder question is whether policy should prioritize an immediate ban tied to an external regulatory taxonomy (USDA categories) or instead create a narrower, administrable standard that balances welfare with the scientific need for some studies under strict oversight.
Two implementation gaps matter practically. First, the bill relies on USDA pain-category nomenclature without explaining who makes the initial category assignment for a proposed NIH-supported project.
USDA categories are part of the Animal Welfare Act regulatory system; NIH traditionally relies on IACUCs and PHS Policy for protocol review. Translating protocol descriptions and IACUC determinations into a legal compliance decision tied to USDA categories will require administrative rules or internal NIH guidance, and those mapping decisions will drive outcomes for many borderline protocols.
Second, the statute contains no waiver or emergency-exemption mechanism and does not establish enforcement processes, remedial steps, or penalties. That absence forces NIH to decide how strictly to implement the ban: whether to treat category assignments as disqualifying at submission, to require post-award remediation, or to terminate awards that later receive a D/E designation.
The bill also creates a path-dependent effect: projects that are scientifically valuable but cannot be redesigned without D/E-level procedures may move to non-NIH funding sources or to jurisdictions with different regulatory regimes, potentially shifting, rather than eliminating, the conduct of high-pain research. These implementation choices will determine whether the law reduces total harmful procedures or merely reshuffles where they occur.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.